Clinical trial

Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer

NCT01658462

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-05-01

PhasePHASE2

Study timeline

Study start (actual)2013-05-01Date precision: month

Registry last updated2026-09-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

DocetaxelDRUG · verified · RxNorm: docetaxel

NintedanibDRUG · verified · RxNorm: nintedanib

Docetaxel: increase of the doseDRUG

Sponsors & collaborators

Centre Oscar Lambretlead sponsor

Boehringer Ingelheimcollaborator

Mapped research locations

LilleFrance1 ReimsFrance1 ToursFrance1 LimogesFrance1 Vandœuvre-lès-NancyFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01658462 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.